Future directions in tumor immunotherapy: CTLA4 blockade.
Gulley
James L
JL
Clinical Immunotherapy Group, National Cancer Institute, Bethesda, MD 20892, USA.
Dahut
William L
WL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D015703:Antigens, CD / Q000187:drug effects* / Q000276:immunology; D000943:Antigens, Differentiation / Q000187:drug effects* / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D007249:Inflammation / Q000139:chemically induced; D000074324:Ipilimumab; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; C556707:Ctla4 protein, mouse; D000074324:Ipilimumab